Evommune(EVMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EVMN Evommune

Market Closed 11-13 16:00:00 EST

7.63

-0.39

-4.86%

盘后7.63

+0.000.00%

19:30 EST

High8.20	Low7.45	Vol723.35K
Open8.18	D1 Closing8.02	Amplitude9.41%
Mkt Cap315.50M	Tradable Cap151.71M	Total Shares41.35M
T/O5.68M	T/O Rate3.64%	Tradable Shares19.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":7.63,"timestamp":1794603600000,"preClose":8.02,"halted":0,"volume":723351,"hourTrading":{"tag":"盘后","latestPrice":7.63,"preClose":7.63,"latestTime":"19:30 EST","volume":390,"amount":2975.7,"timestamp":1794616206655,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04862842892768076,"floatShares":19882900,"shares":41349900,"eps":-2.609,"marketStatus":"Market Closed","change":-0.39,"latestTime":"11-13 16:00:00 EST","open":8.18,"high":8.2,"low":7.445,"amount":5681536.8482574,"amplitude":0.09414,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.609,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":8.02,"postHourTrading":{"tag":"盘后","latestPrice":7.63,"preClose":7.63,"latestTime":"19:30 EST","volume":390,"amount":2975.7,"timestamp":1794616206655,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7697630961500624,"impliedVol":3.0417,"impliedVolPercentile":0.972},"requestUrl":"/m/hq/s/EVMN/wiki","defaultTab":"wiki","newsList":[{"id":"2683008045","title":"Evommune Price Target Cut to $25.00/Share from $28.00 by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2683008045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683008045?lang=en_us&edition=fundamental","pubTime":"2026-11-14 02:29","pubTimestamp":1794594540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EVMN/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683024075","title":"RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2683024075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683024075?lang=en_us&edition=fundamental","pubTime":"2026-11-14 00:56","pubTimestamp":1794588973,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Evommune, Inc., with a price target of $21.00. According...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-evommune-inc-evmn-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-evommune-inc-evmn-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683509480","title":"Analysts Offer Insights on NA Companies: Builders Firstsource (BLDR), Pelthos Therapeutics (PTHS) and Evommune, Inc. (EVMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2683509480","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683509480?lang=en_us&edition=fundamental","pubTime":"2026-11-13 22:40","pubTimestamp":1794580816,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Builders Firstsource (BLDR), Pelthos Therapeutics (PTHS) and Evommune, In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-builders-firstsource-bldr-pelthos-therapeutics-pths-and-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-builders-firstsource-bldr-pelthos-therapeutics-pths-and-evommune-inc-evmn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0868494617.USD","EVMN","PTHS","XHB","BK4141","LU1814569148.SGD","BLDR","NA","BK4588","BK4086","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683548020","title":"Evommune Reports Third-Quarter Results and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2683548020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683548020?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:50","pubTimestamp":1794520213,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Evommune, Inc. ( ($EVMN) ). On November 12, 2026, Evommune reported third-quarter financial results and busines...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-reports-third-quarter-results-and-pipeline-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-reports-third-quarter-results-and-pipeline-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683548396","title":"Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2683548396","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683548396?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:40","pubTimestamp":1794519641,"startTime":"0","endTime":"0","summary":"Evommune (NYSE:EVMN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.84) by 1.19 percent. This is a 89.47 percent increase over losses of $(8.07) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63225203/evommune-q3-eps-0-85-misses-0-84-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683751032","title":"Evommune reports Q3 EPS (85c), consensus (86c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2683751032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683751032?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:17","pubTimestamp":1794518225,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $0 vs $10M last year. The Company did not generate any revenue for the three and nine months ended September 30, 2026, compared ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evommune-reports-q3-eps-85c-consensus-86c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evommune-reports-q3-eps-85c-consensus-86c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683732517","title":"Evommune Presents Evo301 Phase 2a Data Showing Primary Endpoint Met in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2683732517","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683732517?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:15","pubTimestamp":1794518143,"startTime":"0","endTime":"0","summary":"Evommune Presents EVO301 Phase 2a Data Showing Primary Endpoint Met in Atopic DermatitisEvommune’s EVO301 met its Phase 2a atopic dermatitis primary endpoint, delivering 33% placebo-adjusted EASI impr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL3kftgb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683517914","title":"Evommune Q3 Net Loss More than Doubles to $30.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2683517914","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683517914?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:11","pubTimestamp":1794517883,"startTime":"0","endTime":"0","summary":"Evommune Q3 net loss more than doubles to $30.88 millionEvommune’s third-quarter 2026 net loss more than doubled year over year to $30.88 million.No revenue was generated, while research and developme","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL5T49Qp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683517844","title":"Press Release: Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2683517844","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683517844?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:05","pubTimestamp":1794517500,"startTime":"0","endTime":"0","summary":"Safety and Tolerability Profile at EADV Congress: In October 2026,Evommune presented additional data from its Phase 2a proof-of-concept. trial of EVO301 in adults with moderate-to-severe atopic dermatitis . in a late-breaking oral presentation at the European Academy of. Dermatology and Venereology  2026 Congress. With only two. injections, EVO301 met the trial's primary endpoint, achieving a 55%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK9077","AD","BK4132","IND.AU","BK4139","307180.KR","EVMN","BK9021","EASI","BK7095","IND","032820.KR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682857385","title":"Evommune Announces Presentations at Three Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2682857385","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682857385?lang=en_us&edition=fundamental","pubTime":"2026-11-09 21:09","pubTimestamp":1794229796,"startTime":"0","endTime":"0","summary":"Evommune Announces Presentations at Three Investor ConferencesEvommune to hold a fireside chat at Stifel Healthcare Conference in New York on Nov. 11, 2026, at 4:40 p.m. ET.Presentation at the 2026 Je","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL6hzKzR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVR","SF","BK4127","BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681029049","title":"Evommune Hosts Webcast to Discuss Evo570 Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2681029049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681029049?lang=en_us&edition=fundamental","pubTime":"2026-11-05 19:37","pubTimestamp":1793878672,"startTime":"0","endTime":"0","summary":"Evommune Hosts Webcast to Discuss EVO570 Licensing DealEvommune will host a prerecorded webcast on EVO570 at 8:30 a.m. ET on Nov. 5, 2026.Management will discuss the oral VAV1-directed molecular glue ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL2HVDjF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015712","title":"China's Hinova Hits 2-1/2-Month High on Licensing Deal with Evommune","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015712","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681015712?lang=en_us&edition=fundamental","pubTime":"2026-11-05 11:13","pubTimestamp":1793848382,"startTime":"0","endTime":"0","summary":"BUZZ-China's Hinova hits 2-1/2-month high on licensing deal with Evommune** Shares of Hinova Pharmaceuticals688302.SSjump as much as 14.8% to 37.97 yuan, highest level since August 20** Stock last up ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M03H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","688302","EVMN","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681143094","title":"Evommune Presents Evo570 Development Plan Targeting Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2681143094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681143094?lang=en_us&edition=fundamental","pubTime":"2026-11-05 07:35","pubTimestamp":1793835314,"startTime":"0","endTime":"0","summary":"Evommune Presents EVO570 Development Plan Targeting Rheumatoid ArthritisEvommune plans to begin Phase 2 development of EVO570 in rheumatoid arthritis in 2027, targeting data in Q4 2028.Phase 1 is expected to start around late January 2027, with healthy-volunteer data due around mid-2027.Rights outside Greater China involve $20 million upfront cash, $10 million in warrants exercisable for Evommune stock, issued at signing.A $10 million milestone is payable at Phase 2 initiation; royalties range from mid-single to low-double-digit percentages of net sales.Preclinical comparisons showed roughly 20-fold greater VAV1 degradation potency than Novartis’ MRT-6160, with maximum degradation of 99% versus 97%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL7pNF01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681942640","title":"Evommune Expands Autoimmune Pipeline Through License and Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2681942640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681942640?lang=en_us&edition=fundamental","pubTime":"2026-11-05 07:30","pubTimestamp":1793835006,"startTime":"0","endTime":"0","summary":"Evommune, Inc. ( ($EVMN) ) has provided an update. On November 4, 2026, Evommune entered an exclusive license agreement with Hinova Pharmaceuticals...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/evommune-expands-autoimmune-pipeline-through-license-and-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/evommune-expands-autoimmune-pipeline-through-license-and-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681091268","title":"Evommune Licenses Evo570 from Hinova for $30 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2681091268","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681091268?lang=en_us&edition=fundamental","pubTime":"2026-11-05 07:12","pubTimestamp":1793833930,"startTime":"0","endTime":"0","summary":"Evommune Licenses EVO570 From Hinova for $30 Million UpfrontEvommune agreed to license worldwide rights outside Greater China to Hinova Pharmaceuticals’ EVO570, an investigational oral VAV1 degrader.T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL7dFsP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688302","BK0239","BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681099352","title":"Evommune Licenses Hinova Autoimmune Drug in up to $1.1 Billion Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2681099352","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681099352?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:23","pubTimestamp":1793831014,"startTime":"0","endTime":"0","summary":"Evommune licenses Hinova autoimmune drug in up to $1.1 billion dealNov 4 (Reuters)-EvommuneEVMN.Nsaid on Wednesday it had licensed rights to an experimental autoimmune disease treatment from China's H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL3N46L2H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN","688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681964900","title":"Evommune - to Use Proceeds to Advance Clinical Programs Including Evo570","url":"https://stock-news.laohu8.com/highlight/detail?id=2681964900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681964900?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:10","pubTimestamp":1793830200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5DCWY7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681961780","title":"Evommune - Private Placement at $6.04 Per Share for Gross Proceeds of $30 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2681961780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681961780?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:10","pubTimestamp":1793830200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5DCWY7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EVMN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681096173","title":"Evommune Announces $30 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2681096173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681096173?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:10","pubTimestamp":1793830200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA5DCWY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681950410","title":"Evommune - to Pay $30 Mln Upfront, up to $1.10 Bln Milestones, Plus Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2681950410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681950410?lang=en_us&edition=fundamental","pubTime":"2026-11-05 06:02","pubTimestamp":1793829720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nTUA3NQQDM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVMN","BK4139","BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.evommune.com","stockEarnings":[{"period":"1week","weight":0.1474},{"period":"1month","weight":0.3224},{"period":"3month","weight":-0.4792},{"period":"6month","weight":-0.6671},{"period":"1year","weight":-0.5812},{"period":"ytd","weight":-0.5543}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Evommune, Inc. is a company incorporated in Delaware in April 2020 and headquartered in Palo Alto, California. It is a clinical-stage biotechnology company focused on developing innovative therapies targeting key pathogenic drivers of chronic inflammatory diseases. Its initial clinical development programs are focused on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.","exchange":"NYSE","name":"Evommune","nameEN":"Evommune"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Evommune(EVMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Evommune(EVMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Evommune,EVMN,Evommune股票,Evommune股票老虎,Evommune股票老虎国际,Evommune行情,Evommune股票行情,Evommune股价,Evommune股市,Evommune股票价格,Evommune股票交易,Evommune股票购买,Evommune股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Evommune(EVMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Evommune(EVMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}